Evidence map›Paper›PMID 27453930›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2016

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes.

Brianne M Bettcher, Ryan Fitch, Matthew J Wynn, Matthew A Lalli, Jonathan Elofson, Laura Jastrzab, Laura Mitic, Zachary A Miller, Gil D Rabinovici, Bruce L Miller and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Brianne M BettcherRocky Mountain Alzheimer's Disease Center, Departments of Neurosurgery and Neurology, University of Colorado Anschutz School of Medicine, Aurora, CA, USA; Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Ryan FitchMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Matthew J WynnMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Matthew A LalliNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA.
Jonathan ElofsonMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Laura JastrzabMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Laura MiticMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Zachary A MillerMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Gil D RabinoviciMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Bruce L MillerMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Aimee W KaoMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Kenneth S KosikNeuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, USA.
Joel H KramerMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
University Memory and Aging Center · USUniversity of California, San Francisco · USUniversity of California, Santa Barbara · US

Funding

PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Mechanisms of Executive Decline in Normal AgingR01AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kaitlin B Casaletto, JOEL H KRAMER · 2009 to 2026
$8.3M
Effects of chronic inflammation on brain structure and functionR01AG048234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2015 to 2019
$3.2M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
Understanding the molecular functions of progranulin and granulin in FTLDR01NS095257 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAO, AIMEE · 2015 to 2019
$1.9M
Neurodevelopmental Trajectories Towards Neurodegenerative DiseaseK23AG048291 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, ZACHARY A · 2015 to 2019
$912k
Cognitive and Neural Correlates of Inflammation in Healthy Older AdultsK23AG042492 · NIA · UNIVERSITY OF COLORADO DENVER · PI BETTCHER, BRIANNE MAGOUIRK · 2012 to 2016
$716k
NIA NIH HHS K23 AG042492NIA NIH HHS K23 AG048291NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG032289NIA NIH HHS R01 AG045611NIA NIH HHS R01 AG048234NINDS NIH HHS R01 NS095257
6 · The paper itself

Abstract

introductionMCP-1 and eotaxin-1 are encoded on chromosome 17 and have been shown to reduce hippocampal neurogenesis in mice. We investigated whether these chemokines selectively associate with memory in individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia.

methodsMCP-1 and eotaxin-1 were assayed in controls, MCI, and AD dementia patients with varying phenotypes (n = 171). A subset of 55 individuals had magnetic resonance imaging (MRI) scans available. Composite scores for cognitive variables were created, and medial temporal lobe volumes were obtained.

resultsAn interaction was noted between MCP-1 and eotaxin-1, such that deleterious associations with memory were seen when both chemokines were elevated. These associations remained significant after adding APOE genotype and comparison (non-chromosome 17) chemokines into the model. These chemokines predicted left medial temporal lobe volume and were not related to other cognitive domains. DISCUSSION: These results suggest a potentially selective role for MCP-1 and eotaxin-1 in memory dysfunction in the context of varied MCI and AD dementia phenotypes.

Indexed as

ChemokinesEpisodic memoryInflammationNeuroimagingNeuropsychology

Identifiers

PMID27453930
PMCPMC4941041
OpenAlexW2471609794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.